ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Rheumatology

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

15,993Medicare Part D Prescriptions Filled, Including Refills

Rank: 5 out of 416

$3M Total Retail Price of All Prescriptions

Rank: 3 out of 416

1,299 Patients Receiving at Least One Drug in Part D
80%Patients 65 Years and Older
38% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in California
Lower avg

Schedule Two
Controlled Substances

3% of this provider’s 1,299 patients filled at least one prescription for a schedule two drug, compared to an average of 2%.

Schedule Three
Controlled Substances

17% of this provider’s 1,299 patients filled at least one prescription for a schedule three drug, compared to an average of 12%.

Risky Drugs to Seniors

1% of this provider’s 12,593 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

25% of this provider’s prescriptions were for brand-name drugs, compared to an average of 27%.

Prescription Price

$188 was the average price of a prescription from this provider, compared to $166 among peers.

Prescriptions per Patient

12 is the average number of prescriptions (including refills) per patient, compared to an average of 10.


This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in California
METHOTREXATE 1,041 851 1 2
HYDROCODONE-ACETAMINOPHEN 982 638 S3 2 4
PREDNISONE 892 674 3 1
ALENDRONATE SODIUM 460 414 4 5
SIMVASTATIN 403 343 5 14
FORTEO 376 357 10 6 42
TRAMADOL HCL 373 289 7 7
OMEPRAZOLE 347 275 8 10
FOLIC ACID 337 310 9 50
HYDROXYCHLOROQUINE SULFATE 335 237 10 3
ENBREL 322 182 11 8
LEVOTHYROXINE SODIUM 301 239 12 18
HUMIRA 285 198 13 15
BENAZEPRIL HCL 272 225 14 61
LYRICA 246 153 15 20
LEFLUNOMIDE 238 180 16 12
FUROSEMIDE 236 213 17 35
METFORMIN HCL 233 197 18 28
IBUPROFEN 226 158 19 24
GABAPENTIN 226 166 19 6
AMLODIPINE BESYLATE 215 212 21 16
ATENOLOL 208 196 22 27
SULFASALAZINE 179 125 23 23
POTASSIUM CHLORIDE 175 168 24 51
CELEBREX 151 111 25 11
METOPROLOL TARTRATE 144 130 26 48
CYMBALTA 141 77 27 17
ZOLPIDEM TARTRATE 140 79 28 21
LOVASTATIN 136 117 29 46
LISINOPRIL 133 115 30 25
LEUCOVORIN CALCIUM 132 102 31 37
ALLOPURINOL 123 106 32 13
MELOXICAM 123 102 32 9
ALPRAZOLAM 120 98 34 168
LOSARTAN POTASSIUM 112 91 35 33
WARFARIN SODIUM 103 94 36 59
TRIAMTERENE-HCTZ 100 89 37 92
AMITRIPTYLINE HCL 99 52 R 38 43
PEN NEEDLE 99 94 38 89
METOPROLOL SUCCINATE 96 96 40 53
NAPROXEN 95 67 41 34
ENALAPRIL MALEATE 76 72 42 140
CIMZIA 74 0 43 96
LANTUS 70 34 44 102
ROPINIROLE HCL 66 52 45 127
HYDROCHLOROTHIAZIDE 66 53 45 36
SERTRALINE HCL 65 42 47 100
CITALOPRAM HBR 63 62 48 106
INSULIN SYRINGE 61 38 49 112
FAMOTIDINE 59 52 50 91
ATORVASTATIN CALCIUM 57 46 51 29
ACETAMINOPHEN-CODEINE 57 31 S3 51 45
PLAVIX 56 56 53 74
PRAVASTATIN SODIUM 56 46 53 62
SIMPONI 54 43 55 99
CLONIDINE HCL 54 51 55 119
NIFEDIPINE ER 53 44 57 104
DETROL LA 53 37 57 210
MIRTAZAPINE 52 45 59 155
REMICADE 52 36 59 77
RANITIDINE HCL 52 44 59 56
CIPROFLOXACIN HCL 51 35 62 111
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Dec. 13, 2013.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.